Wednesday, February 10, 2010, 7:44am EST - Canadian Markets open in 1 hour and 46 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Santarus Inc. (SNTS)

 On Feb 9: 3.70 USD   0.00 (0.00%)  
MORE ON SNTS
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Santarus, Inc. (NGM:SNTS) Delayed quote dataEdit
Last Trade: 3.70 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 3.70
Open: N/A
Bid: N/A
Ask: 6.34 x 100
1y Target Est: 5.50
Day's Range: N/A - N/A
52wk Range: 1.05 - 5.82
Volume: 0
Avg Vol (3m): 697,211
Market Cap: 214.88M
P/E (ttm): N/A
EPS (ttm): -0.05
Div & Yield: N/A (N/A%)
Santarus Inc. (SNTS)
1d  5d  3m  6m  1y  2y  5y  max 
 Add SNTS to Portfolio   Download Data

HEADLINES
• SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Tue, Feb 2)
• SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Fri, Jan 15)
• Neutral on Santarus
Zacks.com (Wed, Jan 6)
• Santarus Receives $20 Million
Zacks.com (Wed, Dec 30)
• Santarus eyes Phase III trials for diarrhea drug
at MarketWatch (Wed, Dec 30)
• Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers Diarrhea
Business Wire (Wed, Dec 30)
• 3 Stocks Ready to Roar
at Motley Fool (Wed, Dec 23)
• Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC
Business Wire (Tue, Dec 22)
• Santarus Lippert/Heilshorn Life Sciences Call scheduled for 10:30 am ET today
Vcall (Tue, Dec 15)
• Santarus Announces Webcast Presentation at the Lippert/Heilshorn Life Sciences Virtual Conference
Business Wire (Mon, Dec 14)
• Santarus, JA Solar: Early Volume Plays
at TheStreet.com (Mon, Dec 7)
• SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Mon, Dec 7)
More Headlines for SNTS...
ANALYST
EPS Est (next year) (Dec-09) : 0.33
EPS Est (in 2 years) (Dec-10) : 0.28
Avg Rec (current)*: 2.5
PEG Ratio: 1.03
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Santarus, Inc., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices